Design, Synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase

Journal of Medicinal Chemistry

Volumn 55, Issue 12, 2012, Pages 5868-5877

  Koeberle, Solveigh C ^a   Fischer, Stefan ^a   Schollmeyer, Dieter ^b   Schattel, Verena ^a   Grütter, Christian ^c   Rauh, Daniel ^c   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINOPHENYLAMINO) 7 METHOXY 10,11 DIHYDRODIBENZO[A,D]CYCLOHEPTEN 5 ONE; 2 (2,4 DIFLUORO PHENOXY) 7 METHOXY 10,11 DIHYDRO DIBENZO[A,D]CYCLOHEPTEN 5 ONE; 2 (2,4 DIFLUOROPHENYLAMINO) 7 (1,2 ISOPROPYLIDENGLYCER 3YL) 10,11 DIHYDRO DIBENZO[A,D]CYCLOHEPTEN 5 ONE; 2 (2,4 DIFLUOROPHENYLAMINO) 7 [3 DIHYDROXYPROPOXY] 10,11 DIHYDRO DIBENZO[A,D]CYCLOHEPTEN 5 ONE; 2 (2,4 DIFLUOROPHENYLAMINO) 8 METHOXY 10,11 DIHYDRODIBENZO[A,D]CYCLOHEPTEN 5 ONE; ALBUMIN; ANTIINFLAMMATORY AGENT; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; SKEPINONE L; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHILICITY; IMMUNOCOMPETENT CELL; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

CHEMISTRY TECHNIQUES, SYNTHETIC; DIBENZOCYCLOHEPTENES; DRUG DESIGN; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84863093942     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300327h     Document Type: Article

References (27)

1. Fischer, S.; Koeberle, S. C.; Laufer, S. A. p38Alpha mitogen-activated protein kinase inhibitors, a patent review (2005-2011) Expert Opin. Ther. Pat. 2011, 21, 1843-1866
2. Karcher, S. C.; Laufer, S. A. Successful structure-based design of recent p38 MAP kinase inhibitors Curr. Top. Med. Chem. 2009, 9, 655-676
3. Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein Curr. Med. Chem. 2005, 12, 2979-2994
4. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function J. Pharmacol. Exp. Ther. 1996, 279, 1453-1461
5. Boehm, J. C.; Smietana, J. M.; Sorenson, M. E.; Garigipati, R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J.; Badger, A. M.; Laydon, J. T.; Lee, J. C.; Hillegass, L. M.; Griswold, D. E.; Breton, J. J.; Chabot-Fletcher, M. C.; Adams, J. L. 1-Substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency J. Med. Chem. 1996, 39, 3929-3937
6. de Laszlo, S. E.; Visco, D.; Agarwal, L.; Chang, L.; Chin, J.; Croft, G.; Forsyth, A.; Fletcher, D.; Frantz, B.; Hacker, C.; Hanlon, W.; Harper, C.; Kostura, M.; Li, B.; Luell, S.; MacCoss, M.; Mantlo, N.; O'Neill, E. A.; Orevillo, C.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Sidler, K.; O'Keefe, S. J. Pyrroles and other heterocycles as inhibitors of p38 kinase Bioorg. Med. Chem. Lett. 1998, 8, 2689-2694
7. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heyes, J. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature (London) 1994, 372, 739-746
8. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nature Biotechnol. 2005, 23, 329-336
9. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nature Biotechnol. 2008, 26, 127-132
10. Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition Expert Opin. Drug Discovery 2008, 3, 1427-1449
11. Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition Expert Opin. Drug Discovery 2008, 12, 1409-1425
12. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity Nature Struct. Mol. Biol. 2003, 10, 764-769
13. Koeberle, S. C.; Romir, J.; Fischer, S.; Koeberle, A.; Schattel, V.; Albrecht, W.; Grutter, C.; Werz, O.; Rauh, D.; Stehle, T.; Laufer, S. A. Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor Nature Chem. Biol. 2012, 8, 141-143
14. Laufer, S. A.; Ahrens, G. M.; Karcher, S. C.; Hering, J. S.; Niess, R. Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[ b, e ]oxepin-11-ones and Dibenzo[ a, d ]cycloheptan-5-ones: Novel p38 MAP Kinase Inhibitors J. Med. Chem. 2006, 49, 7912-7915
15. Karcher, S. C.; Laufer, S. A. Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties J. Med. Chem. 2009, 52, 1778-1782
16. Jensen, T. A.; Liang, X.; Tanner, D.; Skjaerbaek, N. Rapid and efficient microwave-assisted synthesis of aryl aminobenzophenones using Pd-catalyzed amination J. Org. Chem. 2004, 69, 4936-4947
17. Napoletano, M.; Norcini, G.; Pellacini, F.; Marchini, F.; Morazzoni, G.; Ferlenga, P.; Pradella, L. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives Bioorg. Med. Chem. Lett. 2001, 11, 33-37
18. Cerelli, M. J.; Curtis, D. L.; Dunn, J. P.; Nelson, P. H.; Peak, T. M.; Waterbury, L. D. Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids J. Med. Chem. 1986, 29, 2347-2351
19. Goldstein, D. M.; Alfredson, T.; Bertrand, J.; Browner, M. F.; Clifford, K.; Dalrymple, S. A.; Dunn, J.; Freire-Moar, J.; Harris, S.; Labadie, S. S.; La, F. J.; Lapierre, J. M.; Larrabee, S.; Li, F.; Papp, E.; McWeeney, D.; Ramesha, C.; Roberts, R.; Rotstein, D.; San, P. B.; Sjogren, E. B.; So, O. Y.; Talamas, F. X.; Tao, W.; Trejo, A.; Villasenor, A.; Welch, M.; Welch, T.; Weller, P.; Whiteley, P. E.; Young, K.; Zipfel, S. Discovery of S -[5-amino-1-(4- fluorophenyl)-1 H -pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)ph enyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase J. Med. Chem. 2006, 49, 1562-1575
20. Han, W.; Liu, C.; Jin, Z. In situ generation of palladium nanoparticles: a simple and highly active protocol for oxygen-promoted ligand-free Suzuki coupling reaction of aryl chlorides Org. Lett. 2007, 9, 4005-4007
21. Ottosen, E. R.; Sorensen, M. D.; Bjorkling, F.; Skak-Nielsen, T.; Fjording, M. S.; Aaes, H.; Binderup, L. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity J. Med. Chem. 2003, 46, 5651-5662
22. Davis, A. M.; Teague, S. J.; Kleywegt, G. J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design Angew. Chem., Int. Ed. Engl. 2003, 42, 2718-2736
23. Teague, S. J. Implications of protein flexibility for drug discovery Nature Rev. Drug Discovery 2003, 2, 527-541
24. Laufer, S.; Thuma, S.; Peifer, C.; Greim, C.; Herweh, Y.; Albrecht, A.; Dehner, F. An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays Anal. Biochem. 2005, 344, 135-137
25. Linsenmaier, S. Entwicklung und Optimierung von in vitro Testverfahren zur Evaluierung von Hemmstoffen der p38 MAP Kinase und JNK3. Dissertation. University of Tuebingen, Tuebingen, Germany, 2006.
26. Schrödinger Suite 2008 Induced Fit Docking protocol; Glide version 5.0; Prime version 1.7; Schrödinger, LLC: New York, 2005.
27. EMD Millipore; 2006; http://www.upstate.com/features/kp.q, (Accessed September 10, 2008).